The latest headlines across every section, pulled from official and open-access sources.
More than 1,000 NHS staff across England have used Martha’s Rule helplines to help identify rapid deterioration of a patient’s condition in the first 18 months of the scheme, new figures show. Latest NHS England data shows that between September 2024 and February 2026, 1,781 calls were made by hospital staff to Martha’s Rule helplines […]
The U.S. Food and Drug Administration today approved an expanded use for Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets to treat agitation associated with dementia due to Alzheimer’s disease in adults.
This report describes an increase in eastern equine encephalitis in northern Vermont during 2023-2024.
This report describes 50 large tuberculosis outbreaks in 23 states during 2017-2023.
FDA is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances.
Heat related illness (2:00), graduate medical education funding and primary care (5:40), foreign body ingestion in children (7:40), fall prevention (11:40), chronic constipation (13:20), and oral corticosteroids in children (15:20).
This week, we feature advances in targeted therapy for HER2-mutant lung cancer, interventions to reduce maternal infection, an emerging treatment for hemophilia A, and a new diagnostic test for tuberculosis. We review Barrett’s esophagus and follow a case of systemic illness with kidney failure. Perspectives address GLP-1 drugs and eating disorders, directed blood donation, generic drug safety, and an in-flight medical emergency.
FDA announces results from the largest and most rigorous examination ever conducted focused on chemical contaminants in infant formula available on the U.S. market.
Failed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells. — The Harvard Drug Group LLC · Class II · Ongoing
Lack of Assurance of Sterility — Harrow Eye LLC · Class II · Ongoing
Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed. — B BRAUN MEDICAL INC · Class II · Ongoing
CGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit. — Leading Pharma, LLC · Class II · Ongoing
Labeling: Incorrect or Missing Lot and/or Exp Date:The expiration date has an extra digit and is printed as 2709114 instead of the correct 270914 (2027-09-14). It is important to note that this error is limited to the vial itself; the saleable unit of the box of 12 bottles has the correct expiration date printed. — Premier Dental Products Co · Class III · Ongoing
Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed. — B BRAUN MEDICAL INC · Class II · Ongoing
Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin — Teva Pharmaceuticals USA, Inc · Class II · Ongoing
Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed. — B BRAUN MEDICAL INC · Class II · Ongoing
Lack of Assurance of Sterility; potential for leakage from the diaphragm port once the foil is removed. — B BRAUN MEDICAL INC · Class II · Ongoing
Discoloration: Firm received five (5) complaints stating that, "Tablets discolored darker than normal and have lighter-colored spots." — Hetero Labs Limited (Unit V) · Class II · Ongoing
The World Health Organization (WHO) has validated Australia for eliminating trachoma as a public health problem, marking a significant milestone in the health of indigenous peoples and in global efforts to combat neglected tropical diseases (NTDs). Trachoma, the world’s leading infectious cause of blindness, no longer represents a public health problem in the country.
Hospital patients at every NHS trust across England can now check their referrals and appointments through the NHS App, making it easier for millions of people to manage their care in one place. Around two-thirds (64%) of all hospital appointments are currently visible through the app, with many patients also able to reschedule or cancel appointments – helping to cut the number of missed […]
The U.S. Food and Drug Administration today announced two major steps as part of an initiative to advance the implementation of real-time clinical trials (RTCT).
On March 31, NCQA released the HEDIS® MY 2026 Volume 2: Technical Update (Technical Update), which provides comprehensive guidance for organizations reporting HEDIS. With this release, the HEDIS Volume 2: Technical Specifications are “frozen” for MY 2026. Why is the HEDIS Technical Update Important? HEDIS is a set of standardized performance measures that enable consumers, […] The post NCQA Releases HEDIS® MY 2026 Volume 2 Technical Update appeared first on NCQA .
Heart failure (HF) affects more than 64 million individuals worldwide, and 20% to 30% of patients with HF and systolic dysfunction have cardiac dyssynchrony due to conduction system disease. JAMA Review author Mihail Chelu, MD, PhD, of Baylor College of Medicine discusses cardiac resynchronization therapy with JAMA Associate Editor David Simel, MD, MHS. Related Content: Cardiac Resynchronization Therapy Leadless Ultrasound-Based Cardiac Resynchronization System in Heart Failure